2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…2019 American Transplant Congress
Use of mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Breaking False Myths
*Purpose: Many centers avoid the use of mTOR inhibitors (mTORi) in hypersensitized kidney transplant recipients and usually employ an immunosuppression based on Mycophenolic Acid (MPA),…2019 American Transplant Congress
Sex Specific Regulation of Podocyte-Specific Genes and Proteins Determines Glomerular Response to mTOR Inhibition
*Purpose: mTOR inhibitors are increasingly used in transplantation with high interindividual variation in proteinuric responses. Although males have higher prevalence and faster progression of glomerular…2019 American Transplant Congress
Sirolimus in Geriatric Kidney Transplantation: Modification of Outcomes by Pre-Transplant History of Malignancy or Cardiovascular Disease
*Purpose: We analyzed the outcomes associated with sirolimus (SRL)-regimens in geriatric (>/=65-year-old) kidney transplant recipients (KTRs).*Methods: Using 2000-2016 Scientific Registry of Transplant Recipients data, Cox…2018 American Transplant Congress
Glycolytic Bias in mTORC2-Deficient Dendritic Cells Potentiates Antigen-Specific Immunity and Accelerates Graft Rejection
The mechanistic target of rapamycin (mTOR) is known to function in two complexes: mTOR complex 1 (mTORC1) and mTORC2. While the function of mTORC1 in…2018 American Transplant Congress
Rapamycin Impairs Human Endothelial Cell Alloimmunogenicity Independent of PD-1/PD-1 Ligand Inhibitory Signaling
Department of Surgery, Duke University Medical Center, Durham, NC.
Rapamycin prevents costimulation blockade (CoB)-resistant rejection in mice and primates, and early human data suggests a similar salutary effect. We have hypothesized that one mechanism…2018 American Transplant Congress
B Cell Reconstitution: 36-Month Analysis of Patients Post-Alemtuzumab Induction Followed by Belatacept-Based Immunosuppression
Alemtuzumab induction combined with belatacept and rapamycin (ABR) maintenance immunotherapy effectively prevents costimulation blockade resistant rejection (CoBRR). We longitudinally investigated kinetics of repopulating B cell…2018 American Transplant Congress
Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction
Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…2018 American Transplant Congress
TORC1 Inhibition Protects Activated Human Regulatory T Cells from Self-Inflicted Damage via Granzyme B
Transplantation Research Center, BWH, Harvard Medical School, Boston, MA.
The safety and efficacy of adoptive transfer of regulatory T cells (Tregs) are being extensively investigated in ongoing clinical trials. However, these trials have been…2018 American Transplant Congress
Lymph Node Reprogramming: Microparticle Delivery of Immune Signals to Induce Tolerance and Prolong Allograft Survival
Introduction: Microparticle (MP) loaded with peptide antigen plus other immune signals and delivered directly into lymph nodes (LN) can result in either pro-inflammatory or anti-inflammatory…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »